Cogent Biosciences Q3 2026 loss widens to $111M
Cogent expects its $791.1 million in cash, cash equivalents and marketable securities to fund operations into late 2028, beyond three pending PDUFA dates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cogent Biosciences, Inc. reported a third-quarter 2026 net loss of $111.4 million, compared with $80.9 million a year earlier. Research and development expenses were $75.1 million versus $69.0 million, and general and administrative expenses were $42.1 million versus $14.4 million. Cash, cash equivalents and marketable securities totaled $791.1 million as of September 30, 2026; Cogent believes these resources will fund operating expenses and capital expenditures into late 2028.
The FDA accepted Cogent’s New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis. The company lists a PDUFA date of November 30, 2026, for GIST, a PDUFA target date of December 30, 2026, and a PDUFA target date of June 29, 2027, for AdvSM. Cogent initiated a single-arm, 40-patient extension cohort of the PEAK trial studying bezuclastinib with sunitinib in first-line GIST. It expects to submit IND applications for its JAK2 and KRAS programs in Q4 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointQuarterly net loss was $111.4 million, compared with $80.9 million a year earlier.
Filing Explained
The release attributes higher third-quarter general and administrative expense to commercial-readiness investments, including personnel and infrastructure for a potential bezuclastinib launch, as well as organizational growth; these are reported expenses, and the launch remains potential.
8-K Event Classification
Key Figures
Key Terms
PDUFA target action date regulatory
New Drug Application regulatory
Investigational New Drug regulatory
ORR medical
PFS medical
Earnings Snapshot
Cogent believes cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements into late 2028.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash does COGT have, and how long does it expect that cash to last?
What was COGT’s third-quarter 2026 net loss?
What will the COGT PEAK extension cohort measure?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|||
|
||||
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
||||
Title of each class |
|
Trading Symbol(s) |
|
Name of each |
|
|
|||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. m
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press release issued by Cogent Biosciences, Inc. on November 5, 2026, furnished herewith. |
|
|
|
104 |
|
The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2026 |
|
|
|
COGENT BIOSCIENCES, INC. |
||
|
|
|
|
|||
|
|
|
|
By: |
|
/s/ John Green |
|
|
|
|
|
|
John Green |
|
|
|
|
|
|
Chief Financial Officer |
Exhibit 99.1
Cogent Biosciences Reports Recent Business Highlights and
Third Quarter 2026 Financial Results
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026
NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date
June 29, 2027
Cash balance of $791.1 million expected to fund operations into late 2028
WALTHAM, Mass. and BOULDER, Colo., November 5, 2026 – Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
“With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “In parallel, our team is preparing for potential approvals in NonAdvanced and Advanced Systemic Mastocytosis and we expect to file INDs for our JAK2 and KRAS pipeline programs this quarter. Backed by a strong balance sheet and a world-class team, we are well positioned to continue our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases.”
Business Highlights
Anticipated Upcoming Milestones
Upcoming Investor Conferences
The live webcasts can be accessed on the Investors & Media page of Cogent’s website at investors.cogentbio.com/events. A replay will be available approximately two hours after completion of each event and will be archived for up to 30 days.
Third Quarter 2026 Financial Results
Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were $791.1 million, as compared to $792.3 million as of June 30, 2026. The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib.
R&D Expenses: Research and development expenses were $75.1 million for the third quarter of 2026 as compared to $69.0 million for the third quarter of 2025. The increase was primarily due to costs incurred to support our on-going SUMMIT, PEAK and APEX clinical trials and to the continued progression of our early stage, preclinical and discovery programs. R&D expenses include non-cash stock compensation expense of $7.5 million for the third quarter of 2026 compared to $5.4 million for the third quarter of 2025.
G&A Expenses: General and administrative expenses were $42.1 million for the third quarter of 2026 as compared to $14.4 million for the third quarter of 2025. The increase was primarily due to continued investments in commercial readiness, including personnel and infrastructure to support the potential launch of bezuclastinib, as well as overall organizational growth. G&A expenses include non-cash stock compensation expense of $9.4 million for the third quarter of 2026 compared to $5.2 million for the third quarter of 2025.
Net Loss: Net loss was $111.4 million for the third quarter of 2026 as compared to a net loss of $80.9 million for the same period of 2025.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: potential FDA approval and commercial launch of bezuclastinib in GIST; potential FDA approval of bezuclastinib in both NonAdvSM and AdvSM; cash runway expected to fund operations into late 2028 and well past all three pending PDUFA action dates for bezuclastinib; plans to submit INDs for the company’s JAK2 and KRAS pipeline programs and to move into clinical development soon; plans to complete dose escalation for CGT4255; and plans to present multiple poster presentations featuring bezuclastinib at ASH 2026 and the contents of those presentations. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
COGENT BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands)
(unaudited)
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
$ |
75,099 |
|
|
$ |
68,989 |
|
|
$ |
221,275 |
|
|
$ |
194,221 |
|
General and administrative |
|
42,085 |
|
|
|
14,366 |
|
|
|
102,154 |
|
|
|
39,649 |
|
Total operating expenses |
|
117,184 |
|
|
|
83,355 |
|
|
|
323,429 |
|
|
|
233,870 |
|
Loss from operations |
|
(117,184 |
) |
|
|
(83,355 |
) |
|
|
(323,429 |
) |
|
|
(233,870 |
) |
Other income: |
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
7,052 |
|
|
|
3,887 |
|
|
|
22,121 |
|
|
|
9,212 |
|
Interest expense |
|
(1,243 |
) |
|
|
(1,459 |
) |
|
|
(3,673 |
) |
|
|
(1,773 |
) |
Other expense, net |
|
(51 |
) |
|
|
(3 |
) |
|
|
(202 |
) |
|
|
(14 |
) |
Total other income, net |
|
5,758 |
|
|
|
2,425 |
|
|
|
18,246 |
|
|
|
7,425 |
|
Net loss |
$ |
(111,426 |
) |
|
$ |
(80,930 |
) |
|
$ |
(305,183 |
) |
|
$ |
(226,445 |
) |
COGENT BIOSCIENCES, INC.
SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
(unaudited)
|
|
September 30, |
|
|
December 31, |
||
|
|
2026 |
|
|
2025 |
||
Cash, cash equivalents and marketable securities |
|
$ |
791,134 |
|
|
$ |
900,765 |
Working capital |
|
$ |
730,466 |
|
|
$ |
846,402 |
Total assets |
|
$ |
832,142 |
|
|
$ |
937,607 |
Total liabilities |
|
$ |
315,884 |
|
|
$ |
301,236 |
Total stockholders’ equity |
|
$ |
516,258 |
|
|
$ |
636,371 |
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653